CatalystAlertBeta

Loading market movers...

Novavax, Inc.

NVAX

$2.02B

Mid Cap

NASDAQBiological Products, (No Diagnostic Substances)Biotechnology🇺🇸North AmericaGAITHERSBURG952 employees

Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company's developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company is also developing vaccines for influenza, respiratory syncytial virus (RSV), avian flu, shingles, Clostridioides difficile, and malaria.

Drugs in Pipeline

30

Phase 3 Programs

14

Upcoming Catalysts

1

Next Catalyst

Jul 26, 2026

19w

Market Overview

Stock performance and key metrics

NVAX News

Catalyst Timeline

1 upcoming, 1 past

No catalysts found.

1 more catalyst beyond 14 days

Start a 48h free trial to see all upcoming catalysts

Drug Pipeline

SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)

COVID-19

RSV-F Vaccine

Respiratory Syncytial Virus (RSV)

NVX-CoV2705 Vaccine

Severe Acute Respiratory Syndrome Coronavirus 2 Infection

NVX-CoV2373

SARS-CoV-2 Infection

CIC Vaccine Co-formulated tNIV2 , SARSCoV-2 rS and Matrix-M Adjuvant

COVID-19

SARS-CoV-2 rS/Matrix M1-Adjuvant

SARS-CoV-2 Infection

RSV F vaccine with adjuvant

Respiratory Syncytial Virus Infections

SARS-CoV-2 rS antigen/Matrix-M Adjuvant

COVID-19

SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period)

SARS-CoV Infection

NVX-CoV2373 (5μg)

COVID-19

NanoFlu

Influenza, Human

XBB.1.5 Vaccine (Booster)

COVID-19

NVX-CoV2515

COVID-19

NVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine

COVID-19

Fluzone HD - Day 0

Influenza

SARS-CoV-2 rS/Matrix-M1 Adjuvant

SARS-CoV-2 Infection

Novavax Quadrivalent vaccine

Influenza

Influenza VLP Vaccine

Influenza

SARS-CoV-2 rS - Phase 1

COVID-19

Quadrivalent VLP Vaccine

Influenza

Influenza VLP Vaccine (recombinant)

Influenza

H5N1 VLP Vaccine

Pandemic Influenza

ICC Vaccine

SARS-CoV Infection

Low dose RSV F Antigen

Respiratory Syncytial Virus Infections

RSV F vaccine (0.5mL injection)

Respiratory Syncytial Virus Infections

Low dose RSV-F Vaccine with Adjuvant

Respiratory Syncytial Virus (RSV)

qNIV Vaccine with Matrix-M Adjuvant

COVID-19

A/H1N1 2009 Influenza VLP Vaccine

Seasonal Influenza

Monovalent Avian Influenza VLP (H7N9)

Influenza (Pandemic)

RSV F Vaccine with Aluminum Phosphate Adjuvant

Respiratory Syncytial Viruses

Drug Name	Phase	Indication	Designations	Patent
SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)	Phase 3	COVID-19	-	-
RSV-F Vaccine	Phase 3	Respiratory Syncytial Virus (RSV)	-	-
NVX-CoV2705 Vaccine	Phase 3	Severe Acute Respiratory Syndrome Coronavirus 2 Infection	-	-
NVX-CoV2373	Phase 3	SARS-CoV-2 Infection	-	-
CIC Vaccine Co-formulated tNIV2 , SARSCoV-2 rS and Matrix-M Adjuvant	Phase 3	COVID-19	-	-
SARS-CoV-2 rS/Matrix M1-Adjuvant	Phase 3	SARS-CoV-2 Infection	-	-
RSV F vaccine with adjuvant	Phase 3	Respiratory Syncytial Virus Infections	-	-
SARS-CoV-2 rS antigen/Matrix-M Adjuvant	Phase 3	COVID-19	-	-
SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period)	Phase 3	SARS-CoV Infection	-	-
NVX-CoV2373 (5μg)	Phase 3	COVID-19	-	-
NanoFlu	Phase 3	Influenza, Human	-	-
XBB.1.5 Vaccine (Booster)	Phase 3	COVID-19	-	-
NVX-CoV2515	Phase 3	COVID-19	-	-
NVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine	Phase 3	COVID-19	-	-
Fluzone HD - Day 0	Phase 2	Influenza	-	-
SARS-CoV-2 rS/Matrix-M1 Adjuvant	Phase 2	SARS-CoV-2 Infection	-	-
Novavax Quadrivalent vaccine	Phase 2	Influenza	-	-
Influenza VLP Vaccine	Phase 2	Influenza	-	-
SARS-CoV-2 rS - Phase 1	Phase 2	COVID-19	-	-
Quadrivalent VLP Vaccine	Phase 2	Influenza	-	-
Influenza VLP Vaccine (recombinant)	Phase 2	Influenza	-	-
H5N1 VLP Vaccine	Phase 2	Pandemic Influenza	-	-
ICC Vaccine	Phase 2	SARS-CoV Infection	-	-
Low dose RSV F Antigen	Phase 2	Respiratory Syncytial Virus Infections	-	-
RSV F vaccine (0.5mL injection)	Phase 2	Respiratory Syncytial Virus Infections	-	-
Low dose RSV-F Vaccine with Adjuvant	Phase 2	Respiratory Syncytial Virus (RSV)	-	-
qNIV Vaccine with Matrix-M Adjuvant	Phase 2	COVID-19	-	-
A/H1N1 2009 Influenza VLP Vaccine	Phase 2	Seasonal Influenza	-	-
Monovalent Avian Influenza VLP (H7N9)	Phase 2	Influenza (Pandemic)	-	-
RSV F Vaccine with Aluminum Phosphate Adjuvant	Phase 2	Respiratory Syncytial Viruses	-	-

Regulatory Approvals

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply